SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 253 filers reported holding SAGE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $775,000 | +4.6% | 37,620 | +138.5% | 0.00% | – |
| Q2 2023 | $741,000 | +18.9% | 15,772 | +6.2% | 0.00% | – |
| Q1 2023 | $623,000 | -8.0% | 14,854 | -16.4% | 0.00% | – |
| Q4 2022 | $677,000 | +58.9% | 17,761 | +63.3% | 0.00% | – |
| Q3 2022 | $426,000 | -14.8% | 10,877 | -29.8% | 0.00% | – |
| Q2 2022 | $500,000 | -22.2% | 15,497 | -20.2% | 0.00% | – |
| Q1 2022 | $643,000 | -45.7% | 19,418 | -30.2% | 0.00% | – |
| Q4 2021 | $1,184,000 | +20.9% | 27,834 | +25.9% | 0.00% | – |
| Q3 2021 | $979,000 | -75.5% | 22,104 | -68.6% | 0.00% | -100.0% |
| Q2 2021 | $4,001,000 | +10.6% | 70,446 | +45.8% | 0.00% | 0.0% |
| Q1 2021 | $3,616,000 | -4.8% | 48,311 | +10.0% | 0.00% | 0.0% |
| Q4 2020 | $3,798,000 | -21.9% | 43,908 | -44.8% | 0.00% | -50.0% |
| Q3 2020 | $4,863,000 | +107.0% | 79,553 | +40.8% | 0.00% | +100.0% |
| Q2 2020 | $2,349,000 | +360.6% | 56,500 | +218.0% | 0.00% | – |
| Q1 2020 | $510,000 | -88.2% | 17,768 | -70.3% | 0.00% | -100.0% |
| Q4 2019 | $4,320,000 | +21.6% | 59,831 | +136.2% | 0.00% | +100.0% |
| Q3 2019 | $3,554,000 | -22.1% | 25,335 | +1.7% | 0.00% | -50.0% |
| Q2 2019 | $4,561,000 | +4.1% | 24,912 | -9.6% | 0.00% | 0.0% |
| Q1 2019 | $4,383,000 | +153.6% | 27,559 | +52.8% | 0.00% | +100.0% |
| Q4 2018 | $1,728,000 | -37.8% | 18,037 | -8.3% | 0.00% | 0.0% |
| Q3 2018 | $2,778,000 | +24.9% | 19,666 | +38.4% | 0.00% | 0.0% |
| Q2 2018 | $2,224,000 | +425.8% | 14,207 | +440.4% | 0.00% | – |
| Q1 2018 | $423,000 | -91.6% | 2,629 | -91.4% | 0.00% | -100.0% |
| Q4 2017 | $5,028,000 | +103.7% | 30,534 | -22.9% | 0.00% | +100.0% |
| Q3 2017 | $2,468,000 | +12240.0% | 39,612 | +16002.4% | 0.00% | – |
| Q2 2017 | $20,000 | -71.8% | 246 | -75.3% | 0.00% | – |
| Q1 2017 | $71,000 | -28.3% | 994 | -48.9% | 0.00% | – |
| Q4 2016 | $99,000 | +800.0% | 1,947 | +456.3% | 0.00% | – |
| Q1 2016 | $11,000 | -97.9% | 350 | -96.2% | 0.00% | – |
| Q4 2015 | $536,000 | +1476.5% | 9,211 | +1024.7% | 0.00% | – |
| Q3 2015 | $34,000 | -87.1% | 819 | -84.4% | 0.00% | – |
| Q1 2015 | $264,000 | +153.8% | 5,264 | +85.8% | 0.00% | – |
| Q4 2014 | $104,000 | – | 2,833 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |